The acquisition follows ​a three-year exclusive research collaboration between the ⁠companies.

“Omniose’s bioconjugation ​platform represents a differentiated approach to ​engineering conjugate vaccines and strengthens our ability to ‌develop ⁠novel vaccines against serious bacterial infections,” said Benjamin Moutier, AstraZeneca’s senior vice president of infectious disease, to Reuters.

Financial terms of the deal ​were not disclosed